Vitamin A and/or high‐dose Ara‐C in the maintenance of remission in acute myelogenous leukaemia in children?
- 1 September 1984
- journal article
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 33 (3) , 256-259
- https://doi.org/10.1111/j.1600-0609.1984.tb02225.x
Abstract
8 children with acute myelogenous leukaemia were brought into remission with a induction regimen containing cytosin arabinoside (Ara‐C), 6‐thioguanine and adriamycin given as the DNA complex. After remissions were obtained, the children were consolidated with high‐dose Ara‐C (2 g/m2 every 12 h for 6 doses) and were given 50000 IU of vitamin A daily as an inducer of differentiation. All children are in continuous relapse‐free survival for periods of 5 to 29 months (mean 14 months).Keywords
This publication has 22 references indexed in Scilit:
- The treatment of acute myelocytic leukemia in patients 30 years of age and youngerAmerican Journal of Hematology, 1982
- High Dose Cytosine Arabinoside in the Management of Refractory Acute LeukaemiaScandinavian Journal of Haematology, 1982
- Retinoic acid enhances growth of human early erythroid progenitor cells in vitro.Journal of Clinical Investigation, 1982
- Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro*1Experimental Cell Research, 1982
- Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells.Journal of Clinical Investigation, 1982
- Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemiaMedical and Pediatric Oncology, 1982
- Acute Myelogenous Leukemia in RemissionNew England Journal of Medicine, 1981
- LOW SERUM-VITAMIN-A AND SUBSEQUENT RISK OF CANCERThe Lancet, 1980
- Treatment of Acute Myelogenous Leukemia in Children and AdultsNew England Journal of Medicine, 1980
- The Effect of Vitamin a Deficiency Upon Experimental Oral CarcinogenesisJournal of Dental Research, 1959